Monte Rosa Therapeutics, Inc. GLUE Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s enterprise value?
- Monte Rosa Therapeutics, Inc. (GLUE) reported enterprise value of $1.2B in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s enterprise value changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s enterprise value increased by 380.6% year-over-year, from $248.74M to $1.2B.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s enterprise value?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s enterprise value has grown at a 11.0% compound annual growth rate (CAGR), from $612.81M to $930.35M.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.